Ponsegromab

Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers[1][2].

Product Specifications

CAS Number

[2368950-15-4]

Product Name Alternative

PF 06946860

UNSPSC

12352203

Target

TGF-beta/Smad

Type

Inhibitory Antibodies

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ponsegromab.html

Purity

99.41

Solubility

10 mM in DMSO

Smiles

[Ponsegromab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]E.J. Roeland, et al. 1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer. VOLUME 32, SUPPLEMENT 5, S1185, SEPTEMBER 01, 2021. Annals of oncology. |[2]Groarke JD, et al. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024 Dec 19;391 (24) :2291-2303.